Patrick Ashe

DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.

AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland.

HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL.

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.